Seventeen life sciences businesses awarded Massachusetts tax incentives to add and retain 426 combined jobs hit 10% of that target as of Dec. 31. Three companies, including Novartis, had reported layoffs either last year or this year.
Edgewise Therapeutics will now focus on a handful of cardiovascular programs including EDG-7500 for hypertrophic cardiomyopathy thanks to the non-dilutive capital from France’s Servier.
Swiss service provider CordenPharma is acquiring AmbioPharm, gaining facilities such as a plant in South Carolina to provide a fully U.S.-based supply.
Riding a newfound surge of interest on infectious disease concerns, Moderna is linking up with a global vaccine foundation in hopes of developing a vaccine to slow the new surge in Ebola underway in the Congo and Uganda.
Expanding in the metabolic space, Eli Lilly has struck a back-loaded licensing deal with South Korea’s Hanmi Pharm for a mid-stage GLP-2 agonist being trialed for short bowel syndrome.
The Securities and Exchange Commission wants to formally kill rules that would have required public companies to report greenhouse gas emissions and risks.
The Excel-based calculator can help companies working on large, multiyear construction or manufacturing projects compute the interest for the contracts.
Plus, Eide Bailly names a slate of managing directors; Baker Tilly principal to head AICPA Tax Executive Committee; PrimeGlobal reports double-digit growth in member revenue; and other news from across the profession.